AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.
AIM ImmunoTech Inc. announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc. This organization represents over 6,700 establishments in Florida's life sciences sector, employing nearly 94,000 individuals.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AIM ImmunoTech Inc. announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc. This organization represents over 6,700 establishments in Florida's life sciences sector, employing nearly 94,000 individuals. Equels expressed pride in contributing to the potential development of therapies for serious diseases, including cancers and COVID-19. This appointment may enhance AIM's influence within Florida's vibrant life sciences industry.
Positive
- Appointment of CEO Thomas K. Equels to BioFlorida's Board may enhance networking opportunities.
- Equels' involvement reflects AIM ImmunoTech's commitment to advancing life sciences in Florida.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BioFlorida is the State’s Leading Life Sciences Industry Association
OCALA, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc., the state’s life sciences industry association.
“The life sciences industry in Florida is vibrant, and we’re excited to welcome Thomas Equels of AIM ImmunoTech, Mark Friedman, PhD of Axogen, Geoff Green of Longeveron, Adam Grossman of ADMA Biologics, and Joe Sardano of Sensus Healthcare,” said Nancy Bryan, President and CEO of BioFlorida, which announced the new board members last week. “Our new board members are leaders in their fields with a passion to unite with our diverse Board of Directors representing the various sectors and regions in Florida with a collective goal to advance the impressive, diverse life sciences ecosystem.”
BioFlorida is the voice of Florida’s life sciences industry, representing 6,700 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ nearly 94,000 Floridians. Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.
“AIM ImmunoTech Inc. is working hard to develop potential therapies for a number of dread diseases — from deadly cancers to COVID-19 — and we’re proud to be able to do this work in Florida,” said Equels. “I’m honored to have been named as a member of the Board of Directors of BioFlorida.”
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
About BioFlorida Inc.
BioFlorida is the voice of Florida’s life science industry, representing 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors that collectively employ 94,000 Floridians. BioFlorida’s member driven initiatives provide a strong business climate for the advancement of innovative products and technology that improve lives and promote economic benefits to the state.
Contacts:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com
AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.